We are proud to share highlights from our recent participation in the Early MDD Detection event hosted by Hytgene. This innovative event focused on the latest breakthroughs in early diagnosis of Major Depressive Disorder (MDD) through advanced molecular diagnostics and biomarker technologies.
Advancing Early Detection of Major Depressive Disorder
The event convened leading scientists, and biotech innovators to explore state-of-the-art biomarker discovery, molecular assay development, and clinical implementation for early and accurate detection of MDD. Eurofins Gentaur and Hytgene showcased cutting-edge solutions designed to transform mental health diagnostics and improve patient outcomes worldwide.
One of the standout advantages of the diagnostic approaches presented at the event, including those by Gentaur and Hytgene, is their remarkable efficiency. These cutting-edge molecular assays offer a way to profile patient samples way faster and at a fraction of the cost compared to traditional Next-Generation Sequencing (NGS) methods. This speed and cost-effectiveness make early MDD detection more accessible and scalable, enabling timely clinical interventions and accelerating research efforts without compromising accuracy or depth of information.
Molecular Diagnostics for Depression: cirRNA Testing Every 4 Weeks with Advanced Software Interpretation
Gentaur introduces a unique and innovative molecular diagnostic test for monitoring depression states through circulating RNA (cirRNA) analysis, conducted every 4 weeks. This cutting-edge assay combines precision with convenience, providing clinicians and researchers with actionable insights into patients’ mental health status.
Unlike traditional Next-Generation Sequencing (NGS) profiles, this cirRNA test is way faster and more cost-effective, enabling regular and scalable monitoring without sacrificing accuracy. Advanced software interpretation tools further enhance data analysis, delivering clear and comprehensive reports for clinical decision-making.
Gentaur Magazines will soon publish an in-depth feature on this groundbreaking technology, showcasing its potential to transform depression diagnostics and personalized mental health care.
Our Engagement and Collaboration
As active participants in molecular diagnostics innovation, we had the opportunity to:
- Discuss the latest advancements in molecular assays for MDD diagnosis.
- Explore collaborative opportunities to enhance early detection technologies.
- Network with experts committed to advancing mental health diagnostics through precision medicine.
Event Highlights in Photos
Our participation in the Early MDD Detection event with Hytgene highlights our dedication to fostering innovation in molecular diagnostics. We look forward to deepening partnerships and accelerating the development of tools that can significantly impact mental health care.
Stay Updated
Follow us for upcoming news on molecular diagnostic innovations and our continued work with partners like Eurofins Gentaur and Hytgene.
- Size: 96 Tests (2x48 tests).
- CE approved IVD testing of Depression.
- (MDD) CircRNA RT-PCR Detection Kit is a cutting-edge diagnostic tool designed to detect Major Depressive Disorder (MDD).
- Using circRNA biomarkers in human saliva sample and reverse transcription polymerase chain reaction (RT-PCR), this kit provides a highly accurate, non-invasive method for MDD screening.
- Ideal for use in both clinical settings and research, it enables identification of depression, classifications of depression (normal, mild depression, moderate depression or severe depression) and evaluate whether depression treatments (SSRIs & SNRIs, rTMS, Ketamine, ECT, etc) are effective to the patients and doctors can adjust treatment plans based on the test results.
- Contact lievengentaur@gmail.com for the Price.